Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Reckitt Benckiser Group (RBGPF) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Reckitt Benckiser Group $93.35, price $65.09, upside +43.4%, quality 76 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
RB
Broad data
Oct 1, 2026
Broad data
Oct 1, 2026
Reckitt Benckiser Group
RBGPF · USUndervalued, solidFair Value upside is positive and quality is strong.
✓Fair value $93.35 · Undervalued (+43.4%)
✓Quality 76/100
!Weak Growth (revenue 5y +0.3 %/yr)
✓Highly profitable · 22.4% net margin (TTM)
✓Moderate debt · generates free cash flow
✓3.3% dividend yield · Well covered
✓Wide moat 82/100
Watch Reckitt Benckiser Group for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 1, 2026.
How to read this chart
60‑month range $43.31 – $84.90 · fair‑value band $54.42 – $142.72 · the $65.09 price screens below the $93.35 fair value. Dashed = 300-day average. As of Oct 1, 2026.
Company profile
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names.
Show more
Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products in the United Kingdom and internationally. The company offers germ protection under Dettol name; intimate wellness under Durex and KY brand names; over the counter under the Biofreeze, Gaviscon, Mucinex, Nurofen, Delsym, Cepacol, and Strepsils names. It also provides personal care products under Clearasil and Veet brand names; vitamins, minerals, and supplements under MegaRed, Airborne, Digestive-Advantage, Movefree, and neuriva names; stain removal under Vanish brand name; and disinfectant products under the Finish, Harpic, and Lysol brands. In addition, the company offers nutritious complementary foods and milk formulas for infant and young children under the Enfamil and Nutramigen brands. Reckitt Benckiser Group plc was founded in 1819 and is headquartered in Slough, the United Kingdom.
Stock analysis
Reckitt Benckiser Group (RBGPF) currently trades at $65.09, while our model-based Fair Value estimate is $93.35, implying the stock looks roughly 30.3% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $115.27 per share, and 13 of the 25 models we run sit above the $65.09 price.
Bear case: the Asset-Based group reads lowest at $10.81, and 12 of the 25 models stay below the price. Evidence for this calculation is high.
Scenario range: $54.42 (bear) to $142.72 (bull), the price of $65.09 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 76/100 (high quality), in the Consumer Defensive sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Reckitt Benckiser Group reported revenue of £14.2B in FY2025 versus £13.2B in FY2021, a compound +1.8%/yr. Reported net income was £3.2B in FY2025.
Key figures
Market cap $42.6B · P/E ratio 10.0 · P/S ratio 2.23 · EPS (TTM) $6.53 · Dividend yield 3.3% · Net margin 22.4% · Return on equity 44.2% · Return on assets (EBIT) 8.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 57 out of 100 (medium confidence).
What moves the price
The share trades about 23% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −29% fair-value upside, at 43%, RBGPF screens cheaper than that median.
Fair Value models
Bear $54.42
Fair Value $93.35
Bull $142.72
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($3.33 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$35.86
$58.02
$90.13
79
Growth DCF
$37.11
$57.47
$85.58
78
Owner Earnings
$67.04
$103.83
$157.13
76
All 25 models by family
DCF Models
FCF DCF
$35.86
$58.02
$90.13
79
Owner Earnings
$67.04
$103.83
$157.13
76
5Y Revenue Exit
$24.34
$40.92
$61.21
72
5Y EBITDA Exit
$59.52
$104.22
$154.85
74
5Y P/E Exit
$64.37
$112.95
$162.11
70
10Y Revenue Exit
$27.28
$43.01
$62.41
66
10Y EBITDA Exit
$50.28
$86.07
$131.38
67
10Y P/E Exit
$53.32
$92.00
$136.73
63
Earnings-Based
Graham-Dodd
$45.09
$113.71
$147.71
65
PEG = 1.0
$20.98
$29.97
$38.96
57
EPV
$59.71
$71.56
$81.92
74
Dividend Discount
Gordon GGM
$26.84
$51.10
$85.41
66
DDM Multi-Stage
$26.84
$40.77
$55.85
66
Multiples
P/E Multiple
$104.43
$139.24
$174.05
63
P/S Multiple
$35.52
$47.36
$59.20
58
P/B Multiple
$66.58
$88.77
$110.97
55
EV/EBIT
$100.66
$138.00
$175.35
66
EV/EBITDA
$84.43
$116.37
$148.31
67
EV/Revenue
$19.70
$33.02
$46.34
52
Asset-Based
NCAV (Graham)
$8.07
$10.81
$16.14
54
Growth DCF
Growth DCF
$37.11
$57.47
$85.58
78
Rev-Margin DCF
$24.34
$41.50
$60.35
72
Economic Profit
Residual Income
$35.77
$43.32
$72.93
74
ROIC Compounder
$63.04
$79.87
$97.87
72
Growth Earnings
Growth-Adj P/E
$80.69
$115.27
$149.85
67
Notify me when RBGPF reaches fair value
Put RBGPF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
76/100
Of which business quality 70 · Market factors (momentum, volatility) 54
Profitability
73
Margins and returns on capital today
Quality Growth
64
Are margins and returns improving?
Cashflow
51
Earnings quality: real cash, not paper profit
Fin. Strength
56
Balance sheet, leverage, solvency risk
Investment
97
Disciplined investing over empire-building
Low Volatility
64
Calm price path (market factor)
Momentum
52
Price trend over the last 3–12 months (market factor)
52W Momentum
48
Distance to the 52-week high (market factor)
Net Issuance
100
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
40/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
+0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−0.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.3%
Start year 2020 (pandemic). Over 10 years: +4.8% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) (mathematically smoothed) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Smoothed = median of all growth paths between the years of the window (trend line on the logarithm of earnings per share): a single extreme year cannot distort the rate. The reported figure stays in the tooltip.
+16.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.8%
Dividend (yield on the price)3.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.23.9% vs 6.6%, picking up
Profit margin 2019 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.−13% → 30%
2025 sits 113% above its own trend. The rate follows the median trend of the last 5 years, not that single year.
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+6.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+0.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (figures in GBP, UK: IMF forecast 2.3% a year to 2030, 3.3% from 2016 to 2025) that is about +4.1% a year for the price and −1.7% for the forecasts.
Forecast 2026 (sales)−9.0%
Forecast 2027 (sales)+3.4%
Projected 2028 (sales)+3.3%
Projected 2029 (sales)+3.1%
Projected 2030 (sales)+2.9%
Watch RBGPF, get fair value alerts →
Earlier news
News mood ⓘNews mood, the average tone of recent news (99 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Positive
Recent news coverage is more positive than average.
- RECKITT INVESTS UP TO $600 MILLION TO ACCELERATE U.S.-BASED INNOVATION, EXPAND ACCESS TO HEALTHCARE PRODUCTS, AND STRENGTHEN SUPPLY RESILIEN
- First Bellwether Trial Today Against Reckitt Benckiser’s Mead Johnson in NEC Baby Formula MDL Led by Levin Papantonio
- Reckitt Announces Expiration and Results of Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Company Notes due 2
- Reckitt Announces Pricing Terms for Previously Announced Any and All Tender Offer and Consent Solicitation for Mead Johnson Nutrition Compan
Compare Reckitt Benckiser Group with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 241 stocks
Beats the industry median on 8/15 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
Context: sector, industry, market
- Is the Consumer Staples sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Household & Personal Products stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Colgate-Palmolive Company CL | $86.52 | $56.16 | −35% |
| Hindustan Unilever Limited HINDUNILVR | ₹1,836 | ₹775.25 | −58% |
| Kenvue Inc KVUE | $17.80 | $12.72 | −29% |
| The Estée Lauder Companies Inc EL | $90.19 | $44.21 | −51% |
| Kimberly-Clark Corporation KMB | $98.77 | $83.77 | −15% |
| Henkel AG HEN | €66.35 | €82.61 | +25% |
| Church & Dwight Co CHD | $95.62 | $65.04 | −32% |
| Beiersdorf Aktiengesellschaft, BEI | €75.40 | €69.09 | −8% |
| Puig Brands, S.A PUIG | €17.84 | €24.28 | +36% |
| Marico Limited MARICO | ₹781.35 | ₹493.84 | −37% |
Explore undervalued stocks
More undervalued Consumer Defensive stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Reckitt Benckiser Group (RBGPF) overvalued or undervalued?
As of Oct 1, 2026, our model estimates a fair value of $93.35 versus a price of $65.09, about +43% upside (undervalued).
What is the fair value of RBGPF?
Our model-based fair value for Reckitt Benckiser Group is $93.35 (as of Oct 1, 2026), built from audited fundamentals. The current price: $65.09.
What is the quality score of RBGPF?
Reckitt Benckiser Group has a Quality Score of 76/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Reckitt Benckiser Group (RBGPF)?
Our model-based price target is the fair value of $93.35 (as of Oct 1, 2026) from 25 valuation models. Cautious scenario $54.42, optimistic scenario $142.72. It is a calculation from audited fundamentals, not an analyst target.
What is the Reckitt Benckiser Group stock forecast for 2026?
Our models put fair value at $93.35, about +43% upside versus a price of $65.09 (undervalued). Cautious scenario $54.42, optimistic scenario $142.72. The calculation is refreshed regularly with new filings.
What is the revenue of Reckitt Benckiser Group (RBGPF)?
Reckitt Benckiser Group reported trailing-twelve-month revenue of about £14.2B (latest available figure, as of Oct 1, 2026).
Does Reckitt Benckiser Group pay a dividend?
Reckitt Benckiser Group currently shows a dividend yield of about 3.26% relative to its recent price (as of Oct 1, 2026).
What growth is priced into Reckitt Benckiser Group (RBGPF)?
For today's price to be fair in a discounted-cash-flow model, Reckitt Benckiser Group would have to grow free cash flow by +6.6 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +0.3 % per year. As of Oct 1, 2026.
What discount rate (WACC) does the fair value of RBGPF use?
Our models discount Reckitt Benckiser Group at 8.1 %: a base by market capitalisation (large), damped by beta 0.25, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Reckitt Benckiser Group that is +6.6 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Reckitt Benckiser Group (RBGPF) delivered so far?
Over the past 5 years revenue at Reckitt Benckiser Group grew +0.3 % a year. The price currently implies +6.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Reckitt Benckiser Group (RBGPF) growing?
The median revenue growth in the sector is +2.8 % a year. That is the yardstick for the growth priced into Reckitt Benckiser Group (+6.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Reckitt Benckiser Group (RBGPF)?
The free-cash-flow yield on the price is 5.48 %: that much free cash flow Reckitt Benckiser Group produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Reckitt Benckiser Group (RBGPF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Reckitt Benckiser Group it is $93.35 per share (as of Oct 1, 2026), against a price of $65.09. It is the blended result of 25 valuation models (cash flow, earnings, asset, dividend).
Is Reckitt Benckiser Group stock overvalued or undervalued in 2026?
As of Oct 1, 2026, RBGPF trades below its calculated fair value: price $65.09, fair value $93.35, a gap of about +43% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of RBGPF?
No. The price is what the market pays today ($65.09); the fair value is what the company's own numbers justify ($93.35). For Reckitt Benckiser Group the two are $28.26 per share apart. That gap is exactly why we show both numbers side by side.
How much is Reckitt Benckiser Group worth?
The market values Reckitt Benckiser Group at about $42.6B (market capitalisation, as of Oct 1, 2026). Per share that is $65.09; our models calculate a fair value of $93.35 per share.
What do the bullish and bearish scenarios say about RBGPF?
Our models span a range for Reckitt Benckiser Group: cautious scenario $54.42, base $93.35, optimistic $142.72 per share (as of Oct 1, 2026, price $65.09). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of RBGPF?
Reckitt Benckiser Group trades at a price-to-earnings ratio of 10.0 (as of Oct 1, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $93.35 is built from several models across several years. Other multiples: PEG 2.2, P/B 5.8, P/S 3.2, EV/EBITDA 13.3.
What is the PEG ratio of RBGPF?
The PEG ratio of Reckitt Benckiser Group is 2.15 (P/E divided by earnings growth, as of Oct 1, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Reckitt Benckiser Group (RBGPF)?
Balance-sheet figures for Reckitt Benckiser Group (as of Oct 1, 2026): return on equity 44.2%, debt of 0.96 per unit of equity. They feed the Quality Score of 76/100, which measures business quality independently of the share price.
How far is RBGPF from its 52-week high?
Reckitt Benckiser Group trades at $65.09, about 23% below its 52-week high of $84.90 and 16% above the low of $56.27 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $93.35 is for.
Which stocks are comparable to Reckitt Benckiser Group?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, Kenvue Inc, The Estée Lauder Companies Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Reckitt Benckiser Group stock attractive at the current price?
The data as of Oct 1, 2026: price $65.09, calculated fair value $93.35 (+43%), Quality Score 76/100, from 25 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of RBGPF calculated?
We run Reckitt Benckiser Group through 25 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $93.35, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Reckitt Benckiser Group currently trades 30 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Reckitt Benckiser Group (RBGPF)?
The closing price on Oct 2, 2026 was $65.09. Our model-based fair value is $93.35, about +43% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Reckitt Benckiser Group right now?
The rarer combination: high quality (76/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide ($54.42 to $142.72). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Where does the earnings growth of Reckitt Benckiser Group (RBGPF) come from?
Earnings per share at Reckitt Benckiser Group grew −0.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +5.5 %, EBIT margin −1.6 %, tax rate −1.0 %, residual (interest, one-offs) −3.2 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Reckitt Benckiser Group
How large is the market capitalisation of Reckitt Benckiser Group (RBGPF)?
The market capitalisation of Reckitt Benckiser Group is $42.6B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Reckitt Benckiser Group (RBGPF)?
The price-to-sales ratio of Reckitt Benckiser Group is 2.23 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Reckitt Benckiser Group (RBGPF)?
Earnings per share at Reckitt Benckiser Group are $6.53 (price ÷ EPS = P/E 10.0). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Reckitt Benckiser Group (RBGPF)?
The dividend yield of Reckitt Benckiser Group is 3.3% (payout 32.5%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Reckitt Benckiser Group (RBGPF)?
The net margin of Reckitt Benckiser Group is 22.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Reckitt Benckiser Group (RBGPF)?
The return on equity (ROE) of Reckitt Benckiser Group is 44.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Reckitt Benckiser Group (RBGPF)?
On an EBIT basis the return on assets of Reckitt Benckiser Group is 8.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Reckitt Benckiser Group (RBGPF)?
The operating margin of Reckitt Benckiser Group is 26.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Reckitt Benckiser Group (RBGPF)?
Revenue at Reckitt Benckiser Group is growing −2.6% versus a year earlier (3y avg −0.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Reckitt Benckiser Group (RBGPF)?
Earnings per share at Reckitt Benckiser Group are growing −13.2% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Reckitt Benckiser Group (RBGPF) carry?
The net debt of Reckitt Benckiser Group is £6.5B (fiscal year 2025, ≈ 3.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Reckitt Benckiser Group in the live analysis
One click puts Reckitt Benckiser Group on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.